Perrigo Promotes Affordable Healthcare Amid Legal Challenges and National Store Brand Month
- Perrigo Company plc promotes store brand OTC products, emphasizing cost-effective healthcare solutions for families in the U.S.
- The company collaborates with retailers to provide FDA-approved self-care products, ensuring quality similar to national brands.
- Perrigo faces class action lawsuits alleging misleading information about its acquired Nestlé baby formula business, impacting its reputation.
Perrigo Champions Accessible Healthcare Amid Legal Challenges
Perrigo Company plc actively celebrates National Store Brand Month in January 2026, focusing on the vital role of store brand over-the-counter (OTC) health and self-care products in making healthcare more accessible for families across the United States. This initiative, created by the Private Label Manufacturers Association, underscores the financial benefits of store brand items, which can save consumers between 25% and 30% compared to national name brands in various self-care categories such as pain relief, allergy care, and cold treatments. By promoting these products, Perrigo aims to emphasize the importance of cost-effective healthcare solutions, particularly during the peak cold and flu season.
As a leading manufacturer and partner for store brand OTC products, Perrigo collaborates with both national and regional retailers to provide effective self-care solutions that meet U.S. Food and Drug Administration (FDA) standards. These products contain the same active ingredients as their branded counterparts, ensuring that consumers receive the quality they expect. During this month-long initiative, Perrigo encourages families to stock their medicine cabinets with essential OTC items like ibuprofen, acetaminophen, cough suppressants, and decongestants, thereby promoting preparedness and informed health choices without the financial burden that often accompanies branded products.
Beyond the celebration of National Store Brand Month, Perrigo faces significant legal challenges. The DJS Law Group and the Schall Law Firm have filed class action lawsuits against the company, alleging violations of the Securities Exchange Act of 1934. The claims center around allegations that Perrigo misled the market regarding the condition of its recently acquired Nestlé baby formula business, which reportedly suffered from substantial underinvestment in maintenance. These legal proceedings may impact the company’s reputation and focus as it continues to advocate for affordable healthcare solutions. With the class period spanning from February 27, 2025, to November 4, 2025, affected shareholders are encouraged to participate in the lawsuits to seek recovery for their losses.
As Perrigo navigates these challenges, its commitment to enhancing individual well-being through accessible self-care options remains a core aspect of its mission. The company’s efforts during National Store Brand Month serve as a reminder of its dedication to empowering consumers and providing effective healthcare solutions during critical times.
Related Cashu News

CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: UNDEFINED) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, t…

MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-b…

Ionis Pharmaceuticals Advances TRYNGOLZA for Hypertriglyceridemia and Diranersen for Alzheimer's Disease
Ionis Pharmaceuticals has made headlines in the biotechnology sector with the promising potential of its drug TRYNGOLZA, which is designed to treat severe hypertriglyceridemia. During a recent healthc…

ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…